Junshi Biosciences
↗Shanghai, China
Junshi Biosciences is a leading innovation-driven biopharmaceutical company based in China, dedicated to the discovery, development, and commercialization of novel therapies. The company has established a comprehensive R&D system covering the entire drug lifecycle, from early-stage discovery to large-scale manufacturing and global commercialization.
Junshi is best known for developing Toripalimab (Loqtorzi), the first Chinese anti-PD-1 monoclonal antibody to receive FDA approval. Their portfolio spans five major therapeutic areas: oncology, autoimmune diseases, chronic metabolic diseases, neurological diseases, and infectious diseases, with a significant focus on first-in-class and best-in-class biologics.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$250M-$500M
Founded:2012
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$1.5B+
Investors:Hillhouse Capital, Lilly Asia Ventures, CICC Capital
STOCK
Exchange:HKEX | SSE
Ticker:1877.HK | 688180.SH
Market Cap:$5.4B
PIPELINE
Stage:Commercial
Lead Drug Stage:Approved (FDA/NMPA)
Modalities:mAb, Bispecific antibody, ADC, Small molecule, RNA
Active Trials:92
Trial Phases:Phase 1: 15 | Phase 2: 10 | Phase 3: 5
FDA Approvals:1
EMA Approvals:1
CORPORATE STRUCTURE
Subsidiaries:TopAlliance Biosciences Inc., Suzhou Union Biopharm Co., Ltd.
Key Partnerships:Coherus BioSciences (US/Canada commercialization of Toripalimab), Eli Lilly (COVID-19 antibody etesevimab), AstraZeneca (Combination trials), LEO Pharma (EU/EEA distribution)
COMPETITION
Position:Leader
Competitors:BeiGene, Innovent Biologics, Hengrui Medicine, Merck (Keytruda), Bristol Myers Squibb (Opdivo)
LEADERSHIP
Key Executives:
Xiong Jun - Chairman
Dr. Zou Jianjun - CEO
Dr. Ning Li - Vice Chairman
Scientific Founders:Xiong Jun
Board Members:Dr. Roy Steven Herbst, Zhang Chun, Dr. Feng Xiaoyuan
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Junshi Biosciences. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.